What is Recursion Pharmaceuticals, Inc.'s revenue?

Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of $6.47M in Q1 2026.

How has Recursion Pharmaceuticals, Inc.'s revenue changed year-over-year?

Recursion Pharmaceuticals, Inc.'s revenue decreased by 56.1% year-over-year, from $14.75M to $6.47M.

What is the long-term trend for Recursion Pharmaceuticals, Inc.'s revenue?

Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s revenue has grown at a 64.6% compound annual growth rate (CAGR), from $10.18M to $74.68M.

Recursion Pharmaceuticals, Inc. RXRX Revenue

Revenue at other companies

DJT

Trump Media & Technology GroupDJT

$871.2K+6.1%

ADMA BiologicsADMA

$114.49M-0.3%

Cal-Maine FoodsCALM

$666.95M-53.0%

Ollie's Bargain Outlet Holdings, Inc.OLLI

$658.93M+14.2%

PhotronicsPLAB

$209.94M-0.5%

First BanCorpFBP

$258.64M+4.2%

Other financials

Income statement

See full

Revenue$6.5M-56.1%

Gross profit-$6.0M+15.0%

Operating income-$128.5M+32.8%

Net income-$117.5M+42.0%

EPS (diluted)-$0.22+56.0%

Balance sheet

See full

Cash & equivalents$665.2M+30.6%

Total debt$88.6M-24.6%

Total equity$1.0B+9.7%

Total assets$1.3B+2.6%

Cash flow

See full

Operating cash flow-$81.1M+38.5%

CapEx$258.0K-85.9%

Free cash flow-$81.4M+39.2%

Valuation

See full

Market cap$1.71B-23.7%

Enterprise value$1.14B-39.8%

P/S25.8×-11.8×

Profitability

See full

Gross margin7.2%—

Operating margin-881.3%-66.8pp

Net margin-842.9%-92.4pp

FCF margin-490.7%-102pp

Returns & leverage

See full

Return on equity-57.2%-14.4pp

Debt / equity0.1×0.0×

Current ratio5.5×+1.4×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Recursion Pharmaceuticals, Inc.'s revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s revenue?: Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of $6.47M in Q1 2026.
How has Recursion Pharmaceuticals, Inc.'s revenue changed year-over-year?: Recursion Pharmaceuticals, Inc.'s revenue decreased by 56.1% year-over-year, from $14.75M to $6.47M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s revenue?: Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s revenue has grown at a 64.6% compound annual growth rate (CAGR), from $10.18M to $74.68M.